New TAVR item added to cart for large scale clinical testing

Key Points There is no single TAVR prosthesis that can be considered ideal for all patients, needing the development of newer technologies. The GENESIS trial tested 40 patients with the Hydra self‐expandable supra‐annular TAVR with promising results in terms of efficacy, paravalvular leak, and pacemaker risk. Future larger experimental trials are needed to better understand its non‐inferiority to prior technologies.